SBIR/STTR Reauthorization Act of 2025
- Sponsor
- Rep. Velázquez, Nydia M. [D-NY-7]
- Committees
- Science, Space, and Technology Committee (primary)
- Last action
- May 1, 2025
Bottom line
The bill aims to strengthen federal support for small business innovation, particularly for underrepresented groups, and accelerate the commercialization of federally funded research, while also addressing national security concerns regarding foreign ownership.
What it actually does
This bill reauthorizes and significantly modifies the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through fiscal year 2030 and beyond. It increases the percentage of federal agency budgets allocated to these programs, enhances competition by expanding fellowship opportunities and application assistance, and improves commercialization efforts through new official designations and simplified Phase III award procedures. It also extends several pilot programs and codifies safeguards against foreign entities of concern to protect national security.
Proponents argue
Proponents argue that the bill is crucial for fostering American innovation, supporting small businesses, and maintaining the nation's technological competitiveness. They highlight the increased funding allocations, expanded outreach to minority institutions and underserved states, and streamlined commercialization pathways as vital for ensuring a robust pipeline of cutting-edge technologies. The security safeguards are also a key selling point for protecting national interests and preventing foreign exploitation of federal research.
Opponents contend
Potential opponents might raise concerns about the significant increase in mandatory set-asides for SBIR/STTR programs, arguing it could divert funds from other critical research initiatives or lead to less efficient allocation of R&D budgets. Some might also question the effectiveness of certain pilot programs or the administrative burden of new reporting requirements. Specific opposition to the foreign ownership safeguards might come from those concerned about overreach or impact on legitimate foreign investment, though this is less likely given the national security context.
The bill is moderately complex but manageable for an informed reader within a reasonable timeframe, allowing for substantive evaluation.
Sec. 101
Extension of SBIR and STTR Authority
This section removes the sunset dates for the core Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, effectively reauthorizing them indefinitely. Specifically, it strikes subsection (m) from Section 9 of the Small Business Act, which previously set an expiration date for SBIR, and removes the 'through fiscal year 2025' language from the STTR authority in Section 9(n)(1)(A). This ensures the programs continue without needing periodic reauthorization votes.
Supporters argue
Proponents argue that indefinite reauthorization provides long-term stability and certainty for small businesses relying on these programs, allowing them to plan and invest with confidence in federal R&D partnerships. This continuity is essential for sustained innovation and economic growth.
Critics contend
No specific organized opposition is typically raised against the reauthorization of these widely supported programs, though some might argue for more frequent legislative review to ensure program effectiveness and adaptation to evolving needs.
Tradeoffs
Ensures program continuity and stability for participants but reduces opportunities for periodic comprehensive review and reform that sunset clauses can compel, potentially limiting adaptability.
Sec. 201
Increased Agency Set-Asides for SBIR and STTR Programs
This section gradually increases the percentage of federal agency extramural research and development budgets that must be allocated to the SBIR and STTR programs. For SBIR, the percentage rises from 3.2% (FY2017-2025) to 4% (FY2026-2027), then 5% (FY2028-2029), 6% (FY2030-2031), and finally 7% (FY2032 and thereafter). For STTR, it increases from 0.45% (FY2016-2025) to 0.5% (FY2026-2027), 0.65% (FY2028-2029), 0.8% (FY2030-2031), and 1% (FY2032 and thereafter. This mandates a larger share of federal R&D funding for small businesses.
Sec. 202
SBIR and STTR Fellowship and Internship Opportunities
This section authorizes federal agencies to provide grants or awards, either directly or in partnership with a third party, to small business concerns that have received SBIR or STTR Phase II awards. The purpose of these grants is to provide fellowship and internship opportunities at the undergraduate, baccalaureate, graduate, and postdoctoral levels in fields important to the Federal agency. It also mandates enhanced outreach to increase the participation of women, socially disadvantaged individuals, and economically disadvantaged individuals in these opportunities, allowing agencies to partner with non-profit organizations for this outreach. Funding can come from existing program funds, up to 3% for most agencies.
Sec. 203
Application Assistance and Enhanced Outreach to Broaden Participation
This section expands the authorized uses of funds for administrative and oversight costs to include providing small business concerns with assistance in applying to the SBIR or STTR programs. This assistance is specifically directed towards carrying out policy directives to increase the participation of States with historically low levels of SBIR or STTR awards. Additionally, it mandates enhanced outreach efforts to increase the participation of individuals conducting research at minority institutions and Hispanic-serving institutions in both SBIR and STTR programs.
Sec. 204
Expanded Technical and Business Assistance (TABA) and I-Corps Participation
This section significantly modifies the Technical and Business Assistance (TABA) program. It now requires federal agencies to authorize recipients of Phase I and Phase II awards to select TABA services, rather than agencies entering agreements with vendors. It adds 'cybersecurity assistance' to the list of eligible services. The maximum TABA funding per project is increased to $6,500 for Phase I (from $5,000) and up to $50,000 for Phase II, clarifying that Phase II TABA can be *in addition* to the award amount. Recipients can now use TABA funds to hire or augment staff for training. Additionally, it mandates that agencies with existing Innovation Corps (I-Corps) programs offer I-Corps participation to SBIR/STTR awardees and allow TABA funds to be used for this purpose.
Sec. 301, 303
Strengthening Phase III Commercialization and Acquisition Workforce Training
Section 301 mandates the Administrator, in coordination with the Secretary of Defense and the Administrator of the General Services Administration, to establish training activities for federal contracting officers and agency acquisition workforce. This training will cover all aspects of Phase III acquisitions under SBIR and STTR programs, including missions, goals, data rights, and the execution of Phase III sole-source award contracts. Section 303 amends the role of Procurement Center Representatives to advocate for the maximum practicable use of Phase III awards and requires agencies to report on actions taken to develop simplified and standardized procedures and model contracts for Phase I, II, and III. It also mandates standardized solicitation provisions and contract clauses for Phase III eligibility.
Sec. 302
Designation of Technology Commercialization Official
This section requires the head of each federal agency with an SBIR or STTR program to designate an existing official within that agency as the 'Technology Commercialization Official.' This official must have sufficient experience with commercialization, provide guidance to award recipients on commercializing and transitioning technologies, and coordinate with the Administrator and other Federal agencies to identify additional markets and commercialization pathways. The official is also required to submit annual reports on commercialization activities and efforts to simplify application processes, and advocate for Phase III awards and other non-SBIR/STTR contracts.
Sec. 402
Extension and Expansion of Direct to Phase II Authority
This section extends the 'Direct to Phase II' authority from fiscal year 2025 to fiscal year 2030. Crucially, it expands this authority from only the National Institutes of Health (NIH), the Department of Defense (DoD), and the Department of Education (DoEd) to *all* federal agencies required to carry out an SBIR program. It sets a limitation that Direct to Phase II awards cannot exceed 10% of an agency's total SBIR funds in a fiscal year, except for NIH, which can use up to 15%. Agencies are also required to report on the number and amount of awards provided under this authority.
Sec. 506
Annual Commercialization Impact Assessment
This section requires the Administrator, in coordination with the head of each federal agency with an SBIR or STTR program, to develop an annual commercialization impact assessment. This assessment will measure various metrics for small businesses that have received at least 50 Phase II awards over a nine-year period. Key metrics include the total dollar value of federal awards (other than SBIR/STTR), total SBIR/STTR Phase I and Phase II awards, average annual gross revenue, revenue from product sales or licensing resulting from SBIR/STTR research, additional investments from non-SBIR/STTR sources, mergers and acquisitions, new spin-out companies, and employee numbers. The findings of this assessment must be reported to Congress and published publicly.
Requires the Department of Defense, Energy, Health and Human Services, NASA, and NSF to transfer not less than 10% of the funds they use for SBIR/STTR administrative, oversight, and contract processing costs to the SBA Administrator. These transferred funds are specifically for increasing SBA's resources for administering the SBIR and STTR programs and cannot be used for programs established under the Small Business Investment Act of 1958.
Sec. 401(a)(2)(B)
Why it matters:This is standard legislative practice for modifying funding mechanisms within existing programs. While significant, it's a reallocation of administrative funds rather than a new program, often placed in technical titles.
Case for: Supporters would argue this ensures the Small Business Administration (SBA) has adequate resources to effectively oversee and administer the growing SBIR/STTR programs, which are critical for small business success and national innovation. It centralizes some administrative capacity to improve program management.
Case against: Agencies might argue that mandating a transfer of their administrative funds to the SBA reduces their own flexibility and control over how they manage their SBIR/STTR programs, potentially leading to inefficiencies or a disconnect between agency-specific needs and the SBA's priorities.
Estimated impact: This provision will result in the transfer of a portion of administrative funds from major federal R&D agencies to the SBA, potentially amounting to millions of dollars annually depending on the administrative budgets of these agencies.
Establishes a pilot program at the National Institutes of Health (NIH) to reduce the time for SBIR/STTR awards. It requires NIH to develop simplified and standardized procedures across all relevant awarding offices to reduce the time between the provision of notice of such awards and the subsequent release of funding to be 'as close to 90 days as possible.' Crucially, it allows the Director of NIH to use alternative peer review procedures, including consultation with appropriate scientific experts, which are deemed to fulfill existing Public Health Service Act requirements for scientific and technical merit assessment. The pilot program terminates on September 30, 2030.
Sec. 504
Why it matters:This is standard legislative practice for adding new pilot programs and modifying existing statutory requirements for a specific agency. The detailed procedural changes are often placed in technical sections.
Case for: Proponents would argue that accelerating the NIH award process is crucial for health-related innovations, allowing small businesses to get critical funding faster and bring life-saving technologies to market more quickly. The alternative peer review aims to maintain scientific rigor while significantly speeding up the process, addressing a long-standing complaint about NIH funding timelines.
Case against: Critics might express concern that streamlining peer review, even under a pilot, could compromise the scientific rigor and quality control traditionally associated with NIH funding, potentially leading to funding less meritorious or less impactful research, or even to funding projects with unforeseen safety issues if not carefully managed.
Estimated impact: This pilot program aims to significantly reduce the award timelines for NIH SBIR/STTR, potentially impacting hundreds of awards annually and accelerating the development of health-related technologies. It represents a notable shift in NIH's review processes for these programs.
This section codifies robust safeguards for small business concerns majority-owned by venture capital operating companies, hedge funds, or private equity firms. It makes such a small business ineligible to receive an SBIR award if the Administrator determines it is, or is majority-owned and controlled by, a 'covered foreign entity.' The bill provides extensive definitions for 'covered foreign entity' and 'foreign entity of concern,' encompassing foreign governments, political parties of foreign countries of concern, non-resident natural persons, and entities organized under or having a principal place of business in a foreign country of concern, as well as those involved in certain espionage or export control violations, or deemed detrimental to national security by the Secretary of Commerce.
Sec. 505
Why it matters:This is standard legislative practice for national security provisions that require precise legal definitions and references to existing statutes and lists to ensure enforceability and avoid ambiguity. The complexity is inherent in the subject matter.
Case for: Proponents would argue that these robust safeguards are essential to prevent foreign adversaries from exploiting federal R&D programs, protecting sensitive technologies, intellectual property, and national security interests. They are a critical defense against economic espionage and technological competition.
Case against: Critics might argue that the broad definitions and extensive reach of 'covered foreign entity' could inadvertently deter legitimate foreign investment or create an overly burdensome compliance regime for small businesses with any international ties, potentially slowing innovation or limiting access to global markets and talent.
Estimated impact: This provision will significantly increase due diligence requirements for federal agencies and small businesses seeking SBIR awards, potentially leading to the denial of awards for companies with certain foreign ownership structures. It aims to protect billions of dollars in federal R&D investment and associated intellectual property.
This section amends the Small Business Act to explicitly include 'SBICs' (Small Business Investment Companies) alongside venture capital operating companies, hedge funds, and private equity firms in various provisions related to SBIR/STTR programs. Specifically, it modifies existing language regarding small business concerns majority-owned by such entities, ensuring that SBICs are considered in the same context as other investment firms for program eligibility and safeguards. It also adds a formal definition for 'SBIC' to the Act.
Sec. 601
Why it matters:This is standard legislative practice for technical clarifications that ensure consistency and comprehensive application of existing policy across various financial entities. It's a refinement of existing law.
Case for: Proponents would argue this technical change ensures consistency and clarity in how different types of investment firms are treated under SBIR/STTR ownership rules, preventing loopholes and ensuring the intent of the safeguards (including those related to foreign ownership) is applied broadly and equitably across all relevant investment vehicles.
Case against: No specific opposition is typically raised against technical clarifications that ensure consistent application of existing policy, as these changes are generally viewed as beneficial for legal precision and program integrity.
Estimated impact: This provision clarifies and potentially expands the scope of ownership considerations for SBIR/STTR eligibility to explicitly include small businesses with SBIC investment, ensuring they are subject to the same rules and safeguards as those with other forms of private investment. The direct fiscal impact is negligible, but it ensures consistent application of program rules.